Diamond V A.I CyberSecurity Scoring
04/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Diamond V in 2026.
No incidents recorded for Diamond V in 2026.
No incidents recorded for Diamond V in 2026.
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Latest updates, reports, and threat intel affecting the global network.
Landmark designation affirms WEI's leadership in delivering enterprise‑wide cybersecurity outcomes across.
Ahmedabad: When cybersecurity experts analysed a full year of malware activity across India, they expected the usual suspects — the tech...
Deal to focus on key sectors including infrastructure, energy, the diamond industry, agriculture, cybersecurity and defense - Anadolu...
B2B security software is growing faster than overall B2B software sales, according to new figures.
Kirby Inland Marine christened the first plug-in diesel hybrid electric towboat in the U.S., the M/V Green Diamond, on the water in Texas.
Although COVID-19 pandemic is still unfolding, class actions related to the coronavirus are already being filed in banking & Debt collection...
Philadelphia District Attorney Seth Williams pleads guilty to accepting a bribe, ending his ongoing federal corruption trial and his tenure...
The third edition of the Bengal Global Business Summit promises to kick off with a big bang. Global consultancy giant PricewaterhouseCoopers...
Optimize cloud infrastructure with VMware for app platforms, private cloud, edge, networking, and security.
Trident versions v25.02.1 through v26.06.1 are susceptible to a vulnerability that could allow an authenticated attacker with access to debug logs to view LUKS passphrases or SMB Active Directory credentials.
Remote Attestation TLS Clients provides multi-language utilities for verifying attested TLS connections. Prior to 0.5.0, the Rust and Go RA-TLS challenge verifiers accepted quote ReportData that was bound to the certificate public key and client nonce but not to the active TLS session before permitting application traffic. An attacker who obtained an enclave TLS private key could relay a genuine quote onto another connection, causing the clients to accept an attacker-terminated connection as the attested enclave. This issue is fixed in 0.5.0.
Enclave OS Virtual runs container workloads inside confidential virtual machines with end-to-end attestation. Prior to tdx-v0.2.43 and tdx-gpu-v0.6.27, the TDX/GPU RA-TLS certificate issuer placed the certificate public-key hash and client nonce in quote ReportData but omitted a value bound to the active TLS session. An attacker who obtained an enclave TLS private key could relay a genuine quote onto another connection, causing a relying party to accept an attacker-terminated connection as the attested enclave. This issue is fixed in tdx-v0.2.43 and tdx-gpu-v0.6.27.
Privasys Go is a maintained fork of the Go programming language that adds RA-TLS support to crypto/tls. Prior to privasys-v0.5.1-go1.26.5, challenge-mode RA-TLS certificates bound quote ReportData to the certificate public key and client nonce but not to the active TLS session. An attacker who obtained an enclave TLS private key could relay a genuine quote onto another connection, causing a relying party to accept a handshake terminated by the attacker as an attested enclave connection. This issue is fixed in privasys-v0.5.1-go1.26.5.
Aegisub is a cross-platform advanced subtitle editor. From 3.2.0 to 3.4.2, Aegisub automatically loads Automation scripts referenced by `Automation Scripts` metadata in `ASS` subtitle projects without asking whether the user trusts the scripts or their authors. An attacker can distribute a crafted `ASS` file together with a referenced malicious Automation script, and opening the `AS` file executes arbitrary code with the privileges of the Aegisub process. From 3.4.0 to 3.4.2, inconsistent handling of embedded `NUL` characters between extension validation and filesystem operations additionally allows a crafted `ASS/Lua` polyglot to reference and execute itself as a single-file variant. The vulnerability is fixed in Aegisub 3.5.0.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.